Close this search box.

We are creating some awesome events for you. Kindly bear with us.

NUS researchers discover new and less toxic anti-cancer drug

Researchers from The National University of Singapore (NUS) have created a new anti-cancer drug which is less harmful to the kidneys.

This novel medicine functions such that it is directly delivered to the mitochondria of cancer cells. Mitochondria is the power generator of cells.

Two active molecules, an anti-cancer drug and a sensitizer, are released at once when the drug reaches the tumour.

Thee molecules will fight the mitochondria of the cancer cells and kill the cells. This ensures that the drug is transferred to its destination, reducing its exposure to other tissues in the body.

Side-effects are reduced and there is a lower possibility of patients developing resistance to the drug with this targeted approach. This is unlike current anti-cancer drugs such as Cisplatin.

Cisplatin is an anti-cancer drug in 1965. Back in the days, it was regarded as a revolutionary form of medicine for treating cancer and increasing cure rates.

Fast-forward to today, Cisplatin and the newer medicine such as the platinum-based anti-cancer drugs are still used in about 40 per cent of all chemotherapy treatments. However, these drugs have dangerous side effects. Some of these include severe kidney dysfunction in patients which may require some patients to undergo dialysis treatment.

Cisplatin is often used as a gold standard and a benchmark for comparing new medicines to as shared by Associate Professor Ang Wee Han from NUS Chemistry.

“Cisplatin is known to kill cancer cells by damaging DNA. But cancer cells are smart, and they have ways to repair this damage and become resistant to the drug treatment. Hence, we need good alternatives that can address drug resistance and the associated side effects,” he said.

Professor Ang and Associate Professor Giorgia Pastorin from NUS Pharmacy had together researched into creating anti-cancer drug which will provide better solutions and be used in place of Cisplatin as a better alternative.

The research was conducted together with Professor Dan Gibson from The Hebrew University of Jerusalem.

Experiments conducted with the new drug found that the tumour from a colon cancer had shrunk such that the tumour became impalpable.

The direct delivery of the drug to the tumour had allowed for this.

This was made possible with the team adding a mitochondria-targeting ligand to the original cisplatin scaffold. The added ligand served as a strong positive charge that strongly corresponded the negative charge of the mitochondrial membrane.

The researchers then observed how the drug was released into the blood and devised a way to contain the drug’s formulation within tiny drug carriers known as liposomal nanovesicles.

The nature of tumours is such that they grow fast, blood vessels, as a result, are unable to properly develop and become leaky.

With this new feature to the drug, permeation of the drug carriers from blood vessels to the tumour microenvironment is achieved and will stay within the tumour, while attacking the cancer cells.

As mentioned earlier, the new drug brought no side effects to the body.

“No sign of kidney inflammation was detected, unlike the use of conventional cisplatin. These results indicate that our invention is a viable alternative to cisplatin,” said Dr Maria Babak, the first author of the study.

Associate Professor Pastorin said that the team wants to push the boundaries and further enhance the drug such that it will allow for total tumour remission and overcome the challenge of drug resistance.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.